Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses.

BMJ Open
Richard PratleyAdie Viljoen

Abstract

In SUSTAIN 7, once-weekly semaglutide demonstrated superior glycated haemoglobin (HbA1c) and body weight (BW) reductions versus once-weekly dulaglutide in subjects with type 2 diabetes (T2D). This post hoc analysis investigated the impact of clinically relevant subject characteristics on treatment effects of semaglutide versus dulaglutide. Analyses by baseline age (<65, ≥65 years), sex (male, female), diabetes duration (≤5, >5-10, >10 years), HbA1c (≤7.5, >7.5-8.5, >8.5% (≤58, >58-69, >69 mmol/mol)) and body mass index (BMI) (<30, 30-<35, ≥35 kg/m2). 194 sites; 16 countries. Subjects with T2D (n=1199) exposed to treatment. Semaglutide 0.5 mg versus dulaglutide 0.75 mg (low-dose comparison); semaglutide 1.0 mg versus dulaglutide 1.5 mg (high-dose comparison), all subcutaneously once weekly. Change in HbA1c (primary endpoint) and BW (confirmatory secondary endpoint) from baseline to week 40; proportion of subjects achieving HbA1c targets (<7%, ≤6.5% (<53, ≤48 mmol/mol)) and weight-loss responses (≥5%, ≥10%) at week 40; and safety. HbA1c and BW reductions (estimated treatment difference ranges: -0.22 to -0.70%-point; -1.76 to -3.84 kg) and proportion of subjects achieving HbA1c targets and weight-loss responses were statistically ...Continue Reading

References

May 28, 2005·Diabetes Care·F Xavier Pi-Sunyer
Dec 24, 2011·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Robert R HenryRichard E Pratley
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Oct 22, 2016·Diabetes, Obesity & Metabolism·Lawrence BlondeRonald M Goldenberg
Feb 6, 2018·The Lancet. Diabetes & Endocrinology·Richard E PratleyUNKNOWN SUSTAIN 7 investigators
Apr 1, 2018·Diabetes, Obesity & Metabolism·Chantal MathieuLuis-Emilio García-Pérez
Apr 25, 2018·The Journal of Clinical Endocrinology and Metabolism·Helena W RodbardPaul Norwood
May 12, 2018·Diabetes, Obesity & Metabolism·Kristin C C PetriRune V Overgaard
Apr 3, 2019·The Journal of Clinical Endocrinology and Metabolism·Vivian A FonsecaJochen Seufert
May 6, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Raffaella GentilellaGiorgio Sesti
Jun 5, 2019·Diabetologia·Ewan R Pearson
Sep 10, 2019·European Heart Journal·Francesco CosentinoUNKNOWN ESC Scientific Document Group

❮ Previous
Next ❯

Citations

Jul 22, 2021·Diabetes, Obesity & Metabolism·Richard E PratleyNino Miresashvili

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.